Scientific Publications

Search by Keyword(s)
Found 16 results

Filters: Author is Stegmaier, K  [Clear All Filters]

Search Results

  • Showing 1-16 of 16 Results
2014
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.Knoechel, B., Roderick JE, Williamson KE, Zhu J., Lohr JG, Cotton MJ, Gillespie SM, Fernandez D., Ku M., Wang H., Piccioni F., Silver SJ, Jain M., Pearson D., Kluk MJ, Ott CJ, Shultz LD, Brehm MA, Greiner DL, Gutierrez A., et al. Nature genetics, 2014/03/02, (2014) Read More / View Supplemental Materials
Abstract
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia.Puissant, A., Fenouille N., Alexe G., Pikman Y., Bassil CF, Mehta S., Du J., Kazi JU, Luciano F., Rönnstrand L., Kung AL, Aster J. C., Galinsky I., Stone RM, DeAngelo DJ, Hemann MT, and Stegmaier K. Cancer cell, 2014/02/10, Volume 25, Issue 2, p.226-42, (2014) Read More / View Supplemental Materials
Abstract
2013
A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.DeAngelo, DJ, Neuberg D., Amrein PC, Berchuck J., Wadleigh M., Sirulnik LA, Galinsky I., Golub T., Stegmaier K., and Stone RM Leukemia research, 2013/11/05, (2013) Read More / View Supplemental Materials
Abstract
Mutational heterogeneity in cancer and the search for new cancer-associated genes.Lawrence, MS, Stojanov P., Polak P., Kryukov GV, Cibulskis K., Sivachenko A., Carter SL, Stewart C., Mermel CH, Roberts SA, Kiezun A., Hammerman PS, McKenna A., Drier Y., Zou L., Ramos AH, Pugh TJ, Stransky N., Helman E., Kim J., et al. Nature, 2013/07/11, Volume 499, Issue 7457, p.214-8, (2013) Read More / View Supplemental Materials
Abstract
In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling.Miller, PG, Al-Shahrour F., Hartwell KA, Chu LP, Järås M., Puissant A., McConkey ME, Cowley GS, Shterental S., Alexe G., Armstrong SA, Root DE, Scadden DT, Hynes R. O., Mukherjee S., Stegmaier K., and Ebert BL Cancer cell, 2013/06/11, (2013) Read More / View Supplemental Materials
Abstract
Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation.Frumm, SM, Fan ZP, Ross KN, Duvall JR, Gupta S., VerPlank L., Suh BC, Holson E., Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J., Roti G., Kung AL, Bradner JE, Tolliday N., and Stegmaier K. Chemistry & biology, 2013/05/23, Volume 20, Issue 5, p.713-25, (2013) Read More / View Supplemental Materials
Abstract
High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma.Crompton, BD, Carlton AL, Thorner AR, Christie AL, Du J., Calicchio ML, Rivera MN, Fleming MD, Kohl NE, Kung AL, and Stegmaier K. Cancer research, 2013/05/01, Volume 73, Issue 9, p.2873-83, (2013) Read More / View Supplemental Materials
Abstract
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition.Puissant, A., Frumm SM, Alexe G., Bassil CF, Qi J., Chanthery YH, Nekritz EA, Zeid R., Gustafson WC, Greninger P., Garnett MJ, McDermott U., Benes CH, Kung AL, Weiss WA, Bradner JE, and Stegmaier K. Cancer discovery, 2013/03/01, Volume 3, Issue 3, p.308-323, (2013) Read More / View Supplemental Materials
Abstract
2011
A method for high-throughput gene expression signature analysis.Peck, D., Crawford ED, Ross KN, Stegmaier K., Golub T. R., and Lamb J. Genome biology, 2011/12/08, Volume 7, Issue 7, p.R61, (2011) Read More / View Supplemental Materials
Abstract
2009
Proteomic and genetic approaches identify Syk as an AML target.Hahn, CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K., Schinzel AC, Ross L., Galinsky I., Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M., Hahn WC, Carr SA, Golub T. R., Kung AL, and Stegmaier K. Cancer cell, 2009/10/06, Volume 16, Issue 4, p.281-94, (2009) Read More / View Supplemental Materials
Abstract
Identification of AML1-ETO modulators by chemical genomics.Corsello, SM, Roti G., Ross KN, Chow KT, Galinsky I., DeAngelo DJ, Stone RM, Kung AL, Golub T. R., and Stegmaier K. Blood, 2009/06/11, Volume 113, Issue 24, p.6193-205, (2009) Read More / View Supplemental Materials
Abstract
2008
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.Hahn, CK, Ross KN, Warrington IM, Mazitschek R., Kanegai CM, Wright RD, Kung AL, Golub T. R., and Stegmaier K. Proceedings of the National Academy of Sciences of the United States of America, 2008/07/15, Volume 105, Issue 28, p.9751-6, (2008) Read More / View Supplemental Materials
Abstract
2007
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.Stegmaier, K., Wong JS, Ross KN, Chow KT, Peck D., Wright RD, Lessnick SL, Kung AL, and Golub T. R. PLoS medicine, 2007/04/01, Volume 4, Issue 4, p.e122, (2007) Read More / View Supplemental Materials
Abstract
2006
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.Hieronymus, H., Lamb J., Ross KN, Peng XP, Clement C., Rodina A., Nieto M., Du J., Stegmaier K., Raj SM, Maloney KN, Clardy J., Hahn WC, Chiosis G., and Golub T. R. Cancer cell, 2006/10/01, Volume 10, Issue 4, p.321-30, (2006) Read More / View Supplemental Materials
Abstract
2005
Gefitinib induces myeloid differentiation of acute myeloid leukemia.Stegmaier, K., Corsello SM, Ross KN, Wong JS, DeAngelo DJ, and Golub T. R. Blood, 2005/10/15, Volume 106, Issue 8, p.2841-8, (2005) Read More / View Supplemental Materials
Abstract
2004
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation.Stegmaier, K., Ross KN, Colavito SA, O'Malley S., Stockwell BR, and Golub T. R. Nature genetics, 2004/03/01, Volume 36, Issue 3, p.257-63, (2004) Read More / View Supplemental Materials
Abstract
  • Showing 1-16 of 16 Results